Omri Amirav-Drory, Ph.D.
General Partner
2-time scientist-founder. Founder at Genome Compiler, founding CEO of Tech.bio. Head of NFX Bio.
Notable Investments
Mammoth Biosciences (Pre-seed)
Twist Bioscience (Early)
C2i Genomics (Series A)
Talus Bio (Seed)
Edity (Seed)
Psyga (Seed)
Pangea (Seed)
See all Omri Amirav-Drory, Ph.D.'s 11 investments on Signal

Operating Experience

General Partner · NFX Capital  · 2020–Present
Founding Partner · tech.bio · 2018–Present
Head of Corporate Development · Twist Bioscience · 2016 – 2018
Founder & CEO · Genome Compiler (acquired) · 2011 – 2016
Postdoctoral Associate · Stanford University School of Medicine · 2007 – 2011

Education & Affiliations

Postdoctoral , Biochemistry and Molecular Biology, Stanford University
Ph.D., Biochemistry, Tel Aviv University
BS, Biochemistry and Molecular Biology, Tel Aviv University

Bio

Omri Amirav-Drory, Ph.D. is the General Partner at NFX Bio. He is a scientist and an operator who has founded, scaled, and invested in some of today’s most important techbio companies.

Before becoming an investor, Omri was the Founding CEO of Genome Compiler, which developed software for genetic engineers and molecular and synthetic biologists. He led the company to a successful acquisition by Twist Bioscience, a next-generation DNA synthesis company currently valued at ~$2.5 Billion. Omri stayed at Twist for almost three years after the acquisition as the Head of Corporate Development.

After leaving Twist, Omri became the Founding Partner at Tech.Bio where he invested and advised in companies like Mammoth Biosciences, immunai, C2i Genomics, and more. Now as an investor, Omri understands what it means to be a Scientist-CEO and is committed to a future where this is the norm, not the exception.

Interests

Proud husband and father of three, two boys and one girl; avid reader of science fiction.